GENE ONLINE|News &
Opinion
Blog

2021-06-21| Trials & Approvals

FDA Greenlights Blueprint Medicines’ Ayvakit for Rare Disease Treatment

by Rajaneesh K. Gopinath
Share To

Blueprint Medicines had a great start to 2020, bagging its very first FDA approval. Its kinase inhibitor, Ayvakit (avapritinib), won the agency’s nod for treating adults with an unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA Exon 18 mutation. Since then, the Cambridge, MA-based company has had a great run with the drug regulator, bagging two more authorizations. Last week, it notched its fourth approval, a second for Ayvakit.

On June 16th, the FDA greenlit Ayvakit for treating adults with advanced systemic mastocytosis (Advanced SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

“Today’s approval of Ayvakit for advanced systemic mastocytosis – the fourth FDA approval across our portfolio in 18 months – culminates nearly a decade of hard work, from our scientists in the laboratory and clinical team conducting trials, to our commercial organization who will now bring Ayvakit to patients,” said Jeff Albers, CEO of Blueprint Medicines.

 

Advanced SM – A Rare Disease

Advanced SM is a rare disease driven by the KIT D816V mutation. Most victims are affected by the non-advanced form of SM, which negatively impacts their quality of life. However, patients suffering from advanced SM experience organ damage due to mast cell infiltration and poor survival. Before Ayvakit, the only therapeutic options available were those that offered symptomatic relief.

“Advanced systemic mastocytosis is a debilitating disease characterized by extensive damage in multiple organ systems due to mast cell infiltration, and new treatment options are urgently needed to address these life-threatening complications,” said Dr. Daniel DeAngelo, from the Dana-Farber Cancer Institute.

Ayvakit is the first FDA-approved therapy for this condition. The full approval is based on results from the Phase 1 EXPLORER trial and Phase 2 PATHFINDER trial. Results showed that the drug demonstrated durable clinical efficacy in advanced SM patients across disease subtypes irrespective of their prior treatment status.

“Avapritinib will clearly establish a new standard of care for patients with advanced systemic mastocytosis. The FDA approval was based on data showing robust and durable responses, including complete remissions and a favorable safety profile. For advanced SM patients, the approval of avapritinib shifts the treatment paradigm toward precision therapy that targets the primary driver of mastocytosis.” Dr. DeAngelo added.

Earlier this year, Blueprint announced that Ayvakit raked in $6 million in net product revenue during the fourth quarter of 2020. In March, the drug had received validation from the EMA for the type II variation marketing authorization application for advanced SM. With no competitor drugs for this indication and a likely EMA approval looming, Blueprint would be anticipating a profitable year in global Ayvakit sales.

Related Article: Biogen’s Controversial Alzheimer’s Drug Wins Historic FDA Approval

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Fake Ozempic Floods Market as FDA Warns Patients to Check Authenticity of Prescriptions
2025-04-16
Bristol Myers Scores FDA Approval for Opdivo-Yervoy Combination as First-Line HCC Therapy
2025-04-14
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top